Loading...

Mega Genomics Limited

6667.HKHKSE
HealthcareMedical - Diagnostics & Research
$7.20
$-0.05(-0.69%)

Mega Genomics Limited (6667.HK) Stock Overview

Explore Mega Genomics Limited’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for 6667.HKStats details for 6667.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for 6667.HKAnalyst Recommendations details for 6667.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Mega Genomics Limited, a genetic testing platform company, provides consumer genetic testing and cancer screening services in China. It offers general testing services comprising ApoE gene testing package that assesses the lipid metabolism capacity and the risk for various related diseases, including Alzheimer's disease; folate metabolic capacity assessment, which analyzes genes related to folate metabolism capacity to determine the risk of developing hyperhomocysteinemia, cardiovascular, and cerebrovascular diseases; Parkinson's disease risk assessment; full-scale cancer risk assessment package; and cardiovascular and cerebrovascular disease risk assessment package. The company also provides advanced testing services, which include Hereditary breast cancer/ovarian cancer genetic testing, Septin9 colorectal cancer screening test, and RNF180/Septin9 gastric cancer screening test; and executive testing services, such as personal whole genome test and whole-exome sequencing package for adults. It offers testing services through self-developed laboratory-developed tests and In-vitro diagnostics testing kits. The company serves health checkup centers, hospitals, and various other customers. Mega Genomics Limited was founded in 2016 and is based in Beijing, China.

CEO

Ms. Lin Lin

Employees

214

Headquarters

401 Health Work, Beijing

Founded

2022

Frequently Asked Questions

Meyka LogoMeyka

Meyka is the best Alternative Data platform powered by AI providing research insights for investors

Connect With Us

Legal Disclaimer

The information provided by Meyka AI PTY LTD is for informational and research purposes only and does not constitute financial, investment, or trading advice. Meyka is a research platform, not a financial advisory service. Investing in financial markets involves risks, and past performance does not guarantee future results. Users should conduct their own due diligence, consult with professional financial advisors, and assess their risk tolerance before making investment decisions. Meyka and its operators are not liable for any financial losses incurred from the use of information on this platform. The data provided is derived from publicly available sources and is believed to be reliable but may not always be accurate or up to date. Users should independently verify information and not rely solely on Meyka for financial decisions. By using Meyka, you acknowledge that it does not provide financial advice or recommendations and agree to seek guidance from a qualified financial professional before making any investment decisions.

© 2025 Meyka AI PTY LTD. All rights reserved.